Tissue Regenix logo

TRX - Tissue Regenix Share Price

0.499p 0.0  5.1%

Last Trade - 4:35pm

Micro Cap
Market Cap £5.57m
Enterprise Value £-7.15m
Revenue £9.46m
Position in Universe th / 1827
Unlock TRX Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the six months ended 30 June 2018, Tissue Regenix Group PLC revenues increased from £1.3M to £5.6M. Net loss decreased 3% to £4.4M. Revenues reflect Orthopaedics segment increase from £0K to £3.2M, BioSurgery segment increase of 73% to £1.5M, US segment increase from £853K to £4.6M, Rest of the world segment increase of 94% to £1M. Lower net loss reflects Finance income increase from £17K to £42K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


TRX Revenue Unlock TRX Revenue

Net Income

TRX Net Income Unlock TRX Revenue

Normalised EPS

TRX Normalised EPS Unlock TRX Revenue

PE Ratio Range

TRX PE Ratio Range Unlock TRX Revenue

Dividend Yield Range

TRX Dividend Yield Range Unlock TRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TRX EPS Forecasts Unlock TRX Revenue
Profile Summary

Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient's body. The dCELL has applications in wound care, heart valve replacement and knee repair. Its products portfolio includes DermaPure, which is used for the treatment of chronic or acute wounds; SurgiPure XD Surgical Tissue Matrix, which is used as a soft tissue patch for the surgical repair of damaged or ruptured soft tissue membranes; OrthoPure XM, which is used to replace the tissue removed during a partial meniscopy; OrthoPure XT, which is a decellurised porcine tendon, and CardioPure, a decellurised human pulmonary or aortic heart valve.

Last Annual December 31st, 2017
Last Interim June 30th, 2018
Incorporated October 17, 2006
Public Since December 21, 2006
No. of Shareholders: n/a
No. of Employees: 79
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange London Stock Exchange (AIM)
Shares in Issue 1,171,971,322
Free Float (0.0%)
Eligible for
TRX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for TRX
Upcoming Events for TRX
Friday 5th June, 2020
Full Year 2019 Tissue Regenix Group PLC Earnings Release
Tuesday 9th June, 2020
Tissue Regenix Group PLC Ordinary Shareholders Meeting
Friday 26th June, 2020 Estimate
Tissue Regenix Group PLC Annual Shareholders Meeting
Similar to TRX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.